Form 10-Q BIOGEN INC. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Biogen (BIIB) PT Lowered to $260 at RBC Capital
October 31, 2024 6:31 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $269.00) while maintaining a Outperform rating.
The analyst comments "3Q showed BIIB remains a company in transition, with some bright spots like ex-U.S. Leqembi, improving operating... More
Biogen (BIIB) PT Raised to $315 at Piper Sandler
October 30, 2024 4:54 PM EDTPiper Sandler analyst Christopher Raymond raised the price target on Biogen (NASDAQ: BIIB) to $315.00 (from $307.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BIIB shares after a solid Q324 beat/FY24 guidance raise. While some may quibble... More
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
October 30, 2024 4:37 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "BIIB posted in-line 3Q revenue, inclusive of Leqembi's beat and Skyclarys' miss, and higher EPS per cost-savings. Leqembi's launch remains affected by infrastructure/logistical challenges, where we continue to expect a gradual, albeit progressing, uptake curve and are... More
